布鲁顿氨酸激酶抑制限制了多发性硬化症疾病驱动的炎症,同时促进了调节性B细胞
Sarah Dybowski1, Jacqueline Thode2, Marie Freier2
1Department of Neurology, University Medical Center Göttingen, Germany.
Neurology(R) neuroimmunology & neuroinflammation
|November 25, 2025
概括
布鲁顿氨酸激酶 (BTK) 抑制有选择地调节免疫细胞,促进调节性B细胞特性,同时抑制中枢神经系统脱髓化模型中的炎症反应. 这为慢性炎症条件提供了有针对性的方法.
科学领域:
- 免疫学 免疫学 免疫学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性硬化症 (MS) 治疗通常会导致广泛的免疫抑制,引发安全问题.
- 需要选择性向致病性免疫细胞的疗法,同时保持基本功能.
- 布鲁顿氨酸激酶 (BTK) 是B细胞和骨髓细胞激活中的一个关键信号分子.
研究的目的:
- 为了研究抑制布鲁顿氨酸激酶 (BTK) 的治疗潜力.
- 评估BTK抑制剂埃沃布鲁丁尼布在中枢神经系统 (CNS) 脱髓化的实验模型中的作用.
- 评估BTK抑制对B细胞和髓状细胞功能的影响.
主要方法:
- 埃沃布鲁丁尼布的作用在各种体内中枢神经系统脱髓化模型中进行了测试.
- 免疫细胞的表型和功能变化使用流细胞计进行了分析.
- 在体外研究中,在Fc受体介导刺激下,研究了骨髓细胞对BTK抑制的反应.
主要成果:
- 埃沃布鲁丁尼布在健康和脱髓化模型中促进了调节性B细胞特性.
- 抑制BTK限制了亲炎性B细胞的分化,并支持了调控功能.
- 抑制BTK减弱了髓状细胞的激活,抑制了促炎性细胞因子,降低了抗原呈现.
结论:
- 抑制BTK是一种选择性和可持续的免疫调节策略,用于慢性中枢神经系统炎症.
- 与广泛的免疫抑制剂不同,BTK抑制保留了必不可少的B细胞功能,同时向致病反应.
- 这种方法具有广泛应用的潜力,可能与其他抗炎剂结合使用.
相关概念视频
T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
B Cell Activation and Differentiation
15.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
15.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
465
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
465
Receptor Downregulation in MVBs
2.7K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
The Blood-brain Barrier
52.2K
Overview
52.2K


